Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "CYP1B1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cytochrome P450 1B1 is an enzyme that in humans is encoded by the CYP1B1 gene.
RNA from cytology samples to diagnose disease
InactiveUS20120231468A1Monitor progressMicrobiological testing/measurementSquamous CarcinomasWhite blood cell
The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., over-expression of beta-2 microgobulin (B2M), keratin 17 (KRT17), interleukin 8 (IL8), or annexin A2 (ANXA2), and under-expression of cytochrome p450 1B1 (CYP1B1) or laminin gamma-2 (LAMC2) can be indicative of the likelihood a subject has squamous cell carcinoma or a precancerous squamous cell disorder. The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. The expression levels of B2M, CYP1B1, KRT17, IL8, ANXA2, or LAMC2 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Water-soluble alpha-naphthoflavone alcohol derivative as well as preparation method and application thereof
ActiveCN104059045AOvercome drug resistanceGood water solubilityOrganic active ingredientsOrganic chemistryHydrogenCYP1B1
The invention relates to a water-soluble alpha-naphthoflavone alcohol derivative as well as a preparation method and application thereof. A structural formula of the water-soluble alpha-naphthoflavone alcohol derivative is shown in a formula (I) shown in the specification, wherein R represents hydrogen or amino carboxylic ester of fatty alcohol and a physiologically acceptable salt thereof, and R1, R2 and R3 are respectively hydrogen or halogen. The invention further relates to a preparation method for the water-soluble alpha-naphthoflavone alcohol derivative and application thereof. The water-soluble alpha-naphthoflavone alcohol derivative can inhibit activity of body CYP1B1 enzyme, so that inhibitory activity of part of the compounds is far higher than that of the alpha-naphthoflavone; the water-soluble alpha-naphthoflavone alcohol derivative can be used for preventing malignant tumors. The water-soluble alpha-naphthoflavone alcohol derivative and anti-tumor drugs are combined for use, so that anti-tumor drug resistance caused by CYP1B1 can be overcome.
Owner:SHANGHAI JIAO TONG UNIV
RNA from cytology samples to diagnose disease
The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., beta-2 microgobulin (B2M) and cytochrome p450 1B1 (CYP1B1). The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. For example, over-expression of B2M and under-expression of CYP1B1 can be indicative of the likelihood a subject has squamous cell carcinoma. Also, over-expression of B2M and over-expression of CYP1B1 can be indicative of the likelihood a subject has a precancerous squamous cell disorder. The expression levels of B2M and CYP1B1 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Kit for genetic detection of uterine cancer
InactiveCN101608230AMicrobiological testing/measurementFluorescence/phosphorescenceGenetic riskFluorescence
The invention discloses a kit for genetic detection of uterine cancer. The kit comprises a specific primer pair and a specific probe pair which are used for detecting the mononucleotide polymorphism loci genotype of an estrogen receptor alpha gene (ER-alpha), a cytochrome P450 17A1 gene (CYP17A1), a cytochrome P450 1A1 gene (CYP1A1) and a cytochrome P450 1B1 gene (CYP1B1), a fluorescent quantitative PCR general component and the like. The kit can evaluate the genetic risk of individuals suffered from the uterine cancer by detecting the polymorphism loci genotype of the genes closely related to the genetic risk of the uterine cancer at the same time.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Methylation biomarker for early detection of gastric cancer
InactiveUS20100075334A1Early detectionAccurate diagnostic systemMicrobiological testing/measurementDNA/RNA fragmentationCYP1B1EMX1
The present application describes a method of diagnosing gastric cancer or a stage in the progression of the cancer in a subject comprising assaying for loss of expression of a marker gene such as POPDC3, CCDC67, LRRC3B, PRKD1, CYP1B1, LIMS2, DCBLD2, LOC149351, ADCY8, BACH2, ALOX5, TCF4, CXXC4, CAMK2N2, EMX1, KCNK9, NCAM2, AMPD3, NOG, SP6, LOC100128675, or CHSY3, or a combination thereof.
Owner:KOREA RES INST OF BIOSCI & BIOTECH
RNA From Cytology Samples To Diagnose Disease
The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., beta-2 microgobulin (B2M) and cytochrome p450 1B1 (CYP1B1). The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. For example, over-expression of B2M and under-expression of CYP1B1 can be indicative of the likelihood a subject has squamous cell carcinoma. Also, over-expression of B2M and over-expression of CYP1B1 can be indicative of the likelihood a subject has a precancerous squamous cell disorder. The expression levels of B2M and CYP1B1 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Nucleic acid encoding CYP1B1 gene mutant and applications thereof
PendingCN111304226AQuick filterEfficient screeningMicrobiological testing/measurementDisease diagnosisWild typeMolecular diagnostics
The invention discloses nucleic acid encoding a CYP1B1 gene mutant and applications thereof, and belongs to the technical field of genetic engineering. Compared with a wild type, the mutant has c.605C>T mutation, and the amino acid sequence of the coded polypeptide has p.Ala202Val mutation. Biological samples susceptible to primary congenital glaucoma can be effectively screened by detecting whether the novel mutant exists; a detection method is rapid, accurate and efficient; the nucleic acid can be used for the molecular diagnosis and differential diagnosis of patients with primary congenitalglaucoma, so that scientific bases can be provided for the early diagnosis and treatment of the patients with the primary congenital glaucoma; and the nucleic acid can be used for screening carrierswith the primary congenital glaucoma, so that genetic counseling advice and guidance can be provided for the carriers, and the probability that offspring suffer from the primary congenital glaucoma can be reduced.
Owner:福州福瑞医学检验实验室有限公司
Plasticizer tracking biomarker, plasticizer tracking genetic chip, and plasticizer tracking biomarker confirmation method
The invention discloses a plasticizer tracking biomarker, a plasticizer tracking genetic chip, and a plasticizer tracking biomarker confirmation method. The biomarker found through the confirmation method is one or more of human gene / protein clusters composed of PPARG, CASP3, PPARA, NR1I2, ESR1, AR, CYP1B1, ABCB1, CYP1A1, VEGFA, ESR2, PPARD, LAMP3, BAX, BCL2, CDO1, CELSR2, CSNK1A1, CYP3A4, MAPK1, MAPK3, MYC, NCOA1, PAPSS1, PAPSS2, SUOX, SLC5A5, AKR1C1, IL4, INHA and PCNA, and is suitable for detecting that whether there is pollution of plasticizers, such as phthalate and the like, in a human body or not.
Owner:舍尔辛格
CYP1B1 enzyme targeting probe precursor for radioactivity <18> F labeling
ActiveCN112341445ASurgical resectionSolve the surface of small animalsOrganic chemistry methodsRadioactive preparation carriersEnzyme bindingTumor specific
The invention discloses a CYP1B1 enzyme targeting probe precursor for radioactivity <18> F labeling. The probe precursor comprises an affinity ligand capable of being combined with CYP1B1 enzyme, a chelating group capable of being used for 18F rapid labeling and a connecting chain used for connecting the ligand and the chelating group; wherein the connecting chain comprises a plurality of ethyleneglycol fragments; the affinity ligand is an alpha-naphthalene flavone derivative, and the chelating group capable of being used for 18F rapid labeling is a 1, 4, 7-triazacyclononane-1, 4-diacetic acid molecule. The CYP1B1 enzyme targeting probe precursor is a molecular probe precursor which can be combined with tumor-specific expressed CYP1B1 enzyme and can be used for 18F labeling, and after radiolabeling, the level of the CYP1B1 enzyme in tumors can be displayed in PET imaging, so that the tumors are visualized. The invention can effectively promote the application of a molecular imaging technology in tumor diagnosis.
Owner:SHANGHAI JIAO TONG UNIV
Sebastiscus marmoratus CYP1B1 gene full-length sequence and cloning method thereof
InactiveCN104450751AInstructions are accurateOxidoreductasesFermentationRNA extractionOpen reading frame
Owner:XIAMEN UNIV
Non-invasive defection kit for screening susceptibility genes of endometrial carcinoma
InactiveCN104450876AReduce morbidityNot easy to cause cross infectionMicrobiological testing/measurementMdm2 ProteinA-DNA
The invention discloses a non-invasive detection kit for screening susceptibility genes of the endometrial carcinoma, belonging to the field of gene detection kits. The invention provides a detection kit which is painless, non-invasive, clean, less in possibility of causing cross infection, and accurate and reliable in result for detecting pathogenic factors and risk factors of endometrial carcinoma. The detection kit comprises a specific primer and a DNA sequencing primer for detecting the genotypes of mononucleotide polymorphic sites, a PCR (polymerase chain reaction) assembly, a PCR production purifying assembly and a DNA sequencing reaction assembly, wherein the specific primer is used for detecting a mononucleotide polymorphic site Msp on a CYP1A1 gene, a mononucleotide polymorphic site Leu432Va1 on a CYP1B1 gene, a mononucleotide polymorphic site MspA1I on a CYP17 gene, a mononucleotide polymorphic site 309 on an MDM2 gene and a mononucleotide polymorphic site C609T on a NQ01 gene. The non-invasive detection kit is mainly applied to the medical and the biological aspects.
Owner:TAIYUAN DEPTH DECODING GENE TECH CO LTD
Methods and kits for diagnosing ulcerative colitis in a subject
The present invention relates to methods and kits for diagnosing ulcerative colitis in a subject. In particular, the present invention relates to a method for diagnosing ulcerative colitis in a subject comprising the steps consisting of determining in a sample obtained from the subject the expression level of at least one gene selected from the group consisting of ADH4, ADH6, ADHFE1, AKR1A1, AKR7A2, ALDH1A3, ALDH1L1, ALDH7A1, AOX1, BCHE, CBR3, CES1, CYP1B1, CYP2E1, CYP2W1, CYP4F11, CYP51A1, ESD, KCNAB2, COMT, GSTA4, GSTP1, INMT, MGST2, SULT2A1, TPMT, UGT1A4, UGT1A9, UGT2B7, ABCA1, ABCA2, ABCB1, ABCC1, ABCC10, ABCC5, ABCC6, ABCG2, ATP7A, SLC1A3, SLC7A5, SLC10A2, SLC15A1, SLC15A2, SLC19A2, SLC19A3, SLC22A3, SLC28A3, SLC29A2, SLC38A1, SLC38A5, SLC47A1, SLCO2B1, SLCO4C1, ARNT, FOXO1, HIF3A, NCOA2, NCOR2, NR1H3, NR3C1, PPARD, PPARGC1A, RARB, RXRB, and THRB.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Furanochalcones as inhibitors of cyp1a1, cyp1a2 and cyp1b1 for cancer chemoprevention
InactiveUS20210284618A1Reduce usageUseful in treatmentOrganic active ingredientsOrganic chemistryNitrosoFuran
The present invention relates to the furanochalcone class of compounds of general formula A. The present invention particularly relates to the synthesis of furanochalcones and their CYP1A1, CYP1A2 and CYP1B1 inhibitory activity. In addition, the invention relates to the prevention or treatment of cancer caused by polyaromatic hydrocarbons (PAHs), 4-nitroquinoline-1-oxide, and N-nitroso-N-methylurea, heterocyclic amines, estrogen and 17β-estradiol, resulting from the inhibition of CYP1A1, CYP1A2 and CYP1B1 enzymes.
Owner:COUNCIL OF SCI & IND RES +1
Water-soluble aza-alpha-naphthoflavone compound and preparation method and medical application thereof
ActiveCN108558840AInhibitory activityGood water solubilityOrganic active ingredientsOrganic chemistryPyridazineQuinoline
The invention discloses a water-soluble aza-alpha-naphthoflavone compound and a preparation method and medical application thereof. The structural formula of the aza-alpha-naphthoflavone compound is shown in formula (I) as shown in specification, wherein Ar stands for nitrogen-containing heterocyclic aromatic, and comprises substituent-containing pyridine, pyridazine, quinoline, thiazole, benzimidazole, benzo [d] pyrazole, pyrrolo [2,3-b] pyridine and physically acceptable salts thereof. The invention further relates to a preparation method and medical application of the water-soluble aza-alpha-naphthoflavone compound. The water-soluble aza-alpha-naphthoflavone compound can inhibit activity of human body CYP1B1 enzyme, and the inhibition activity of parts of compounds is far higher than alpha- naphthoflavone; and the water-soluble aza-alpha-naphthoflavone compound can be used for preventing tumors and overcoming drug resistance of malignant tumors caused by CYP1B1 enzyme.
Owner:SHANGHAI JIAO TONG UNIV
Kit for noninvasive detection of ovarian cancer susceptible gene
The invention provides a kit for noninvasive detection of an ovarian cancer susceptible gene. The kit comprises specific primers and DNA sequencing primers for detecting whether C677T and GSTT1 genes on MTHFR gene are null or present, and for detecting the genotype of 3 mononucleotide polymorphism sites of Leu432Val on CYP1B1 gene, a PCR (polymerase chain reaction) reaction assembly, a PCR product purification assembly, and a DNA sequencing reaction assembly, etc. The kit of the invention assesses the risk grade of ovarian cancer suffering by women through detecting the genotype of 3 mononucleotide polymorphism sites closely related to ovarian cancer occurrence, and finally guides women in targeted prevention of ovarian cancer occurrence in a gene level according to the gene detection result of each examinee, thus lowering the morbidity of ovarian cancer. The invention adopts an oral mucosa cell sampling method, which is painless and noninvasive, and avoids cross infection. The kit of the invention has precise and reliable detection results, so that there is no need to purchase expensive special imported equipment, and the method of the kit is very easy to popularize and promote.
Owner:解码(上海)生物医药科技有限公司
Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen
InactiveUS20090136921A1Improve the level ofConducive to survivalMicrobiological testing/measurementLibrary screeningSmall G ProteinPR - Progesterone receptor
Particular embodiments provide novel and clinically useful DNA methylation predictors of hormone receptor status, and predictors of response to endocrine (e.g., hormonal) and non-endocrine breast cancer therapy. The ESR1 gene, encoding the estrogen receptor (ER) alpha proved to be the preferred predictor of progesterone receptor (PR) status, while methylation of the PGR gene, encoding PR, was the preferred predictor of ER status. ESR1 methylation outperformed hormone receptor status as a predictor of clinical response in patients treated with antiestroges (e.g., tamoxifen), while promoter methylation of the CYP1B1 gene, encoding a tamoxifen and estradiol metabolizing cytochrome P450, predicted response differentially in tamoxifen-treated and non-treated patients. High levels of promoter methylation of the ARHI gene, encoding a RAS-related small G-protein, were shown to be preferred predictors of better survival in patients who had not received tamoxifen therapy.
Owner:UNIV OF SOUTHERN CALIFORNIA
Estrogen metabolite levels and cyp1b1 polymorphisms in lung cancer diagnosis, prognosis, and risk assessment
Systems and methods for determining the prognosis of a patient having CYP1B1-mediated lung cancer and for diagnosing a risk of developing CYP1B1-mediated lung cancer are provided. The systems and methods comprise determinations of the concentration of estrogen metabolites in the lung tissue or a proxy thereof, or polymorphisms in the gene encoding the CYP1B1 protein, which metabolite concentrations or CYP1B1 polymorphisms are associated with a probability of surviving and / or a risk of developing lung cancer.
Owner:INST FOR CANCER RES
Assay kit and method for testing CYP1B1 gene polymorphism through pyrosequencing method
InactiveCN102796813AQuick analysisAccurate analysisMicrobiological testing/measurementNucleotideDrug administration
The invention discloses an assay kit and a method for testing CYP1B1 gene polymorphism through a pyrosequencing method. The assay kit is used for testing the CYP1B1 gene polymorphism, specifically rs1056836(C) G mononucleotide polymorphism. The assay kit comprises a primer, such as SEQIDN.2-4. The assay kit can be used for testing the CYP1B1 gene polymorphism in an accurate, quick and high flux manner, and thus, the individualized drug administration of substrate anti-microtubule like chemotherapeutics and the like can be realized safely, reasonably, effectively.
Owner:周宏灏
Methods for screening compounds for capability to inhibit premalignant squamous epithelial cell progression to a malignant state
InactiveUS20130217594A1Induce apoptosisInhibit motilityMicrobiological testing/measurementLibrary screeningMotilityCYP1B1
Methods for screening compounds for their capability to inhibit CYP1B1-mediated proliferation and motility of and / or to reverse estrogen-induced reduction in apoptosis of premalignant or malignant cells are provided. Kits for practicing the screening methods are also provided.
Owner:INST FOR CANCER RES D B A THE RES CENT OF FOX CHASE CANCER CENT FOX CHASE CANCER CENT
Potent and selective inhibitors of cytochrome p450
Inhibitors of the enzyme cytochrome P450 (CYP), including 1B1 (CYP1B1), 1A1 (CYP1A1) and 19A1 (CYP19A1) are provided, and are useful in medical applications. Disclosed are highly potent and selective compounds that can be used in chemoprevention to ameliorate malignant changes induced by CYP, or to aid in treatment, including restoration of chemotherapeutic efficacy.
Owner:UNIV OF KENTUCKY RES FOUND
Targeting the cyp1b1 enzyme for radioactivity 18 f-labeled probe precursor
ActiveCN112341445BOrganic chemistry methodsRadioactive preparation carriersRadioactive drugEnzyme binding
The invention discloses a radioactive drug targeting CYP1B1 enzyme 18 F-labeled probe precursors; the probe precursors include affinity ligands that can be combined with CYP1B1 enzymes, and can be used for 18 The chelating group of F rapid label and the linking chain that is used to connect part and chelating group; The linking chain comprises multiple ethylene glycol fragments; The affinity part is α-naphthoflavone derivative, available At 18 The chelating group of F rapid labeling is 1,4,7-triazacyclononane-1,4-diacetic acid molecule. The present invention is a kind of CYP1B1 enzyme that can be combined with tumor-specific expression, and can be used for 18 F-labeled molecular probe precursor, after radiolabeling, can show the level of CYP1B1 enzyme in the tumor in PET imaging to visualize the tumor. The invention will effectively promote the application of molecular imaging technology in tumor diagnosis.
Owner:SHANGHAI JIAOTONG UNIV
Application of miRNA‑27b in antitumor drug resistance
The present invention relates to the application of miRNA-27b in anti-tumor drug resistance. Specifically, the present invention studies tumor tissues of tumor patients and conducts large-scale screening of human miRNA libraries through high-throughput microRNA chips. Among a large number of microRNAs, it is found that miR-27b is generally down-regulated in tumors, and miR-27b family members It can improve the sensitivity of tumor cells to anti-tumor drugs. The present invention also finds that miR-27b targets genes such as p53 and CYP1B1 in the tumor drug resistance signaling pathway; promoting p53 and inhibiting CYP1B1 expression can improve the sensitivity of tumors to anti-tumor drugs.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
Multigene assay
Owner:AGENCY FOR SCI TECH & RES +1
Methods and compositions for expansion of hematopoietic stem and/or progenitor cells employing a cytochrome p450 1b1 (cyp1b1) inhibitor or a musashi-2 (MSI2) activator
InactiveUS20190209618A1Enhance regenerative potentialImprove scalabilityOrganic chemistryEther/acetal active ingredientsProgenitorCYP1B1
A method of increasing the self-renewal and / or expansion of hematopoietic stem and / or progenitor cells (HSPCs) is described. Inhibiting the activity and / or expression of cytochrome P450 1B1 (CYP1B1) and / or increasing the expression or activity of Musashi-2 (MSI2) increases the expansion of HSPCs. The HSPCs may be cultured in the presence of a CYP1B1 inhibitor and / or a MSI2 activator. Optionally, the cells may be expanded ex vivo and transplanted into a subject in need thereof.
Owner:MCMASTER UNIV
Nir/pet bimodal probe precursor targeting cyp1b1 enzyme and its preparation and use
ActiveCN113730606BMake up for limitationsImprove accuracyOrganic chemistryGeneral/multifunctional contrast agentsCYP1B1Reactive site
The present invention provides a NIR / PET bimodal probe precursor targeting CYP1B1 enzymes and its preparation method and application. The bimodal probe precursor includes an affinity ligand, a signal group and a A connecting chain of an affinity ligand and a signal group; the affinity ligand is an α-naphthoflavone derivative, and the signal group is a near-infrared fluorescent molecule and can be 18 The F-labeled chelating group NODA; the connecting chain is a glutamic acid chain with multiple chemical reaction active sites. The present invention is a NIR / PET dual-modal probe precursor targeting CYP1B1 enzyme, a specific marker of tumors. By targeting CYP1B1 enzyme, the accuracy of tumor imaging is improved, and at the same time, the dual-modal signal group The introduction effectively overcomes the limitations of single modality probes, promotes the application of CYP1B1 enzyme in vivo imaging in tumor live imaging, and will have good application prospects and clinical transformation value in the early diagnosis of tumors.
Owner:SHANGHAI JIAO TONG UNIV
Genetic testing method for menopause medication instruction
The invention discloses a genetic testing method for menopause medication instruction, comprising the following steps: collecting oral mucosa cells of a subject, extracting the genome DNA, and testing the respective polymorphism of the rs4646903 site on the CYP1A1 gene of the genome DNA, the Leu432Val site on the CYP1B1 gene of the genome DNA, the Val158Met site on the COMT gene of the genome DNA and the Present / Null site on the GSTT1 gene of the genome DNA, thereby evaluating the menopause medication metabolic capability on a gene level and using the medication metabolic capability as the medication instruction.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Combined marker for early diagnosis of liver cancer and its application
ActiveCN113337608BIncreased sensitivityWill not cause disseminationMicrobiological testing/measurementDNA/RNA fragmentationGenes mutationAXIN1
The invention discloses a combined marker for early diagnosis of liver cancer and its application. The combined markers for early diagnosis of liver cancer disclosed in the present invention are FAM78A, MKL1, DCDC2, SR, BCL2L11, CYP1B1, PTPN7, AXIN1, SEMA4D, PROX1, SHH, AK055957, DAB2IP, TBX15, GRASP, PPFIA1 and / or PSD4. Methylation, and mutation of TERT and / or CTNNB1. The present invention performs liver cancer detection by detecting the methylation level of the gene combination in the plasma cfDNA, and has high sensitivity and specificity; in the case of adding the mutation detection of the gene, by simultaneously detecting the methylation of the gene combination and the TERT gene , CTNNB1 gene mutation, effectively improve the sensitivity of early screening.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI +1
Application of MLL-menin inhibitor composition in preparation of anti-hepatoma drug
ActiveCN113769098AReduce expressionImprove bindingOrganic active ingredientsDigestive systemH3K4me3Oncology
The invention provides an application of an MLL-menin inhibitor composition in preparation of an anti-liver cancer drug. The composition is composed of an MLL-menin inhibitor and paclitaxel. According to the composition, H3K4me3 catalyzed by MLL is inhibited, so that the expression quantity of CYP1B1 is reduced, the binding effect of the paclitaxel on tubulin is enhanced, the sensitivity of an in-vitro hepatocellular carcinoma cell line and an in-vivo hepatocellular carcinoma mouse on the paclitaxel is synergistically increased, after the hepatocellular carcinoma which is highly resistant to the paclitaxel and is ineffective by singly using an epigenetic drug MLL-menin inhibitor is treated by the composition, the chemotherapy curative effect is obviously improved. The composition provides a novel chemotherapeutic drug for paclitaxel-resistant hepatocellular carcinoma treatment.
Owner:中国医学科学院肿瘤医院深圳医院
Detection kit of paclitaxel metabolism marker and detection method and application thereof
PendingCN113584162AMicrobiological testing/measurementDNA/RNA fragmentationCYP1B1Paclitaxel metabolism
The invention discloses a detection kit of paclitaxel metabolism markers as well as a detection method and application of the detection kit. The detection kit is used for detecting gene polymorphism of two genes CYP1B1 432C / G and ABCB1C3435T of the paclitaxel metabolism markers, and the kit comprises the following components: a CYP1B1 432C / G amplification primer, a CYP1B1 432C / G sequencing primer, an ABCB1C3435T amplification primer, an ABCB1C3435T sequencing primer and a positive control. According to the present invention, the multiple RPA amplification and the optimized pyrosequencing technology are adopted as the combination to detect the gene polymorphism related to the prediction of the treatment effect and the adverse reaction of the paclitaxel, and the kit can simultaneously detect the CYP1B1 (432C / G) and the ABCB1 (C3435T) gene polymorphism paclitaxel so as to provide the gene perspective suggestion for the clinical personalized medication.
Owner:湖南菲思特精准医疗科技有限公司
Near-infrared fluorescent probe targeting cyp1b1 enzyme and its preparation and use
ActiveCN110396403BPrevent effectImprove detection depthOrganic chemistryFluorescence/phosphorescenceFluoProbesCYP1B1
The present invention provides a near-infrared fluorescent probe targeting a CYP1B1 enzyme, and preparation and use thereof. The fluorescent probe comprises an affinity ligand, a signal group, and a linking chain for linking the ligand and the signal group. The linking chain comprises a plurality of ethylene glycol fragments. The affinity ligand is an alpha-naphthoflavone derivative, and the signal group is a near infrared fluorescent molecule. The near-infrared molecular probe targeting a tumor specific marker CYP1B1 enzyme effectively avoids the influence of introduction of the signal groupon inhibitory activity for the CYP1B1 enzyme, promotes application of the near-infrared molecular probe in the tumor in-vivo imaging, and has a good application prospect and clinical transformation value in the field of early diagnosis of tumor.
Owner:SHANGHAI JIAO TONG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com